Emcure Pharmaceuticals Ltd News

International business to remain key driver for Emcure Pharma in FY27

Emcure expects overseas markets to drive growth in FY27 through product approvals, differentiated offerings and capacity expansion, while domestic business is seen improving

Adani Ports, Radico, KFin among 6 top stock ideas for Aug by Motilal Oswal

Motilal Oswal Wealth Management Research Desk recommends 2 stocks each from the large-cap, mid-cap and small-cap segment for August 2026.

Emcure Pharma up 3% after CDSCO approves semaglutide for MASH treatment

The approval makes the innovator molecule from Novo Nordisk the first and only GLP-1 receptor agonist approved in India for the treatment of the disease.

Emcure broadens Poviztra's use for MASH after CDSCO nod for semaglutide

The drugmaker will market Poviztra for treating MASH after CDSCO approved the new indication for innovator semaglutide, expanding the medicine's approved uses in India

Emcure Pharma makes Gennova wholly owned, names Samit Mehta CEO

Restructuring positions biotech arm to focus on biologics and biosimilar

Stock picks: Anand James of Geojit recommends these 3 SMID shares to buy

Anand James of Geojit Investments has recommended these three mid-and-smallcap stocks to buy today; check target and other details

Emcure Pharmaceuticals Q4 results: Profit jumps 28%, revenue up by 16%

The rise in profits was attributed to the robust performance in international markets and growth in new launches from Emcure's in-house portfolio

Emcure Pharmaceuticals Q4 results: Net profit rises 24% to ₹243.74 crore

Emcure Pharmaceuticals Ltd on Tuesday reported a 24 per cent increase in consolidated net profit at Rs 243.74 crore in the fourth quarter ended March 2026 on the back of robust growth in international business. The company had posted a consolidated net profit of Rs 197.24 crore in the corresponding quarter last fiscal, Emcure Pharmaceuticals Ltd said in a regulatory filing. Consolidated revenue from operations in the fourth quarter stood at Rs 2,469.7 crore as against Rs 2,116.25 crore in the same period a year ago, it added. International business sales were at Rs 1,493 crore, up 25.7 per cent YoY, with strong growth across markets supported by base business ramp-up and new launches, Emcure Pharma said. On the other hand, domestic business sales were at Rs 977 crore, up 5.2 per cent YoY. Softer performance was largely due to the Zuventus portfolio and team reorganisation, it added. Zuventus is a subsidiary of the company. Total expenses in the fourth quarter were higher at Rs ..